ICUI Quote, Financials, Valuation and Earnings

Enovis has a net margin of -2.56% compared to ICU Medical's net margin of -10.02%. ICU Medical's return on equity of -4.64% beat Enovis's return on equity of -26.77%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 49.16%. On the other hand Enovis has an analysts' consensus of $56.30 which suggests that it could grow by 84.35%. Given that Enovis has higher upside potential than ICU Medical, analysts believe Enovis is more attractive than ICU Medical.

ICU Medical has a beta of 0.870, which suggesting that the stock is 13.002% less volatile than S&P 500. In comparison Enovis has a beta of 1.494, suggesting its more volatile than the S&P 500 by 49.355%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are larger than Enovis quarterly revenues of $558.8M. ICU Medical's net income of -$15.5M is higher than Enovis's net income of -$56M. Notably, ICU Medical's price-to-earnings ratio is -- while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.26x versus 0.79x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -2.56% compared to ICU Medical's net margin of 12.62%. ICU Medical's return on equity of -4.64% beat Globus Medical's return on equity of 4.59%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 49.16%. On the other hand Globus Medical has an analysts' consensus of $85.91 which suggests that it could grow by 51.76%. Given that Globus Medical has higher upside potential than ICU Medical, analysts believe Globus Medical is more attractive than ICU Medical.

ICU Medical has a beta of 0.870, which suggesting that the stock is 13.002% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.307%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are larger than Globus Medical quarterly revenues of $598.1M. ICU Medical's net income of -$15.5M is lower than Globus Medical's net income of $75.5M. Notably, ICU Medical's price-to-earnings ratio is -- while Globus Medical's PE ratio is 42.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.26x versus 3.13x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -2.56% compared to ICU Medical's net margin of 8.48%. ICU Medical's return on equity of -4.64% beat Merit Medical Systems's return on equity of 9.19%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 49.16%. On the other hand Merit Medical Systems has an analysts' consensus of $108.73 which suggests that it could grow by 29.51%. Given that ICU Medical has higher upside potential than Merit Medical Systems, analysts believe ICU Medical is more attractive than Merit Medical Systems.

ICU Medical has a beta of 0.870, which suggesting that the stock is 13.002% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.358%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are larger than Merit Medical Systems quarterly revenues of $355.4M. ICU Medical's net income of -$15.5M is lower than Merit Medical Systems's net income of $30.1M. Notably, ICU Medical's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 41.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.26x versus 3.63x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Penumbra has a net margin of -2.56% compared to ICU Medical's net margin of 12.1%. ICU Medical's return on equity of -4.64% beat Penumbra's return on equity of 3.62%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 49.16%. On the other hand Penumbra has an analysts' consensus of $313.81 which suggests that it could grow by 33.87%. Given that ICU Medical has higher upside potential than Penumbra, analysts believe ICU Medical is more attractive than Penumbra.

ICU Medical has a beta of 0.870, which suggesting that the stock is 13.002% less volatile than S&P 500. In comparison Penumbra has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.734%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Penumbra offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Penumbra pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are larger than Penumbra quarterly revenues of $324.1M. ICU Medical's net income of -$15.5M is lower than Penumbra's net income of $39.2M. Notably, ICU Medical's price-to-earnings ratio is -- while Penumbra's PE ratio is 221.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.26x versus 7.47x for Penumbra. Usually stocks with elevated PS ratios are considered overvalued.